SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet (GOOG) is trending as discussions revolve around its AI capabilities, especially the Gemini 3 model, and potential market dominance. Community members are weighing bullish and bearish perspectives, with some pointing to new all-time highs and others anticipating a pullback. A multi-million dollar NATO cloud services deal has also sparked interest.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

OSCR is trending due to uncertainty around the Affordable Care Act (ACA) subsidies, sparking volatility as the White House considers a two-year extension with modified eligibility. Community discussions revolve around the potential impact on the company's business model, with some seeing a buying opportunity and others anticipating further declines. Traders are closely watching potential support levels and debating the sustainability of the recent price action amid the broader healthcare sector's performance.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune ($ALT) is trending amid community discussions around potential buyout speculation, particularly involving Sanofi ($SNY), and anticipation for upcoming data releases. While some investors express optimism for a short squeeze and long-term growth driven by Pemvidutide's potential in MASH and obesity, others raise concerns about data integrity and trial design, sparking debate among bulls and bears.

Nukkleus, Inc. is a financial technology company, which engages in the provision of blockchain-enabled technology solutions. It also offers software and technology solutions for worldwide crypto and foreign exchange transactions with a focus on the movement of funds via crypto rails and back-to-back access to fiat conversion in a compliant regulated fashion. It operates through the following geographical segments: United States, United Kingdom, and Malta. The company was founded on May 24, 2019 and is headquartered in New York, NY.

Nukkleus Inc - Ordinary Shares - New

Nukkleus Inc

Nukkleus is trending amid discussions about its acquisition of Star 26 Capital and potential synergies within the aerospace and defense sectors. Community members are actively speculating on upcoming news and a possible short squeeze, with some expressing bullish sentiment based on the company's low float and perceived undervaluation. Despite recent volatility, investors are closely monitoring the stock's movement and awaiting further developments.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending amid optimism surrounding its role in AI infrastructure, particularly after Google's Gemini 3 AI model success with custom chips. The community is discussing its potential to challenge Nvidia's GPU dominance, with some highlighting significant options activity and analyst upgrades. Despite broader market volatility, many see dips as buying opportunities, emphasizing the company's solid fundamentals and upcoming earnings.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community discusses potential ETF impacts and future price movements. Bullish sentiment is fueled by anticipation of increased adoption and institutional interest, while some traders express caution, citing XRP's historical price action and correlation with Bitcoin. Community members are debating short-term volatility versus long-term potential.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst discussions around potential political implications and legal battles involving Donald Trump, with community members debating his influence and future prospects.  Some are focused on potential connections to ongoing investigations, while others are commenting on the stock's performance and its relationship to broader market trends and political events. The conversation reflects polarized opinions and speculation about the company's value and direction.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending amid discussions about potential investigations related to past associations and concerns about their influence on the market, particularly regarding Bitcoin and MicroStrategy. The community is actively debating JPM's role in market manipulation and its relationship with crypto, with some advocating for boycotts and shorting the stock. Additionally, JPM's adoption of blockchain and crypto as collateral is being discussed.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG) is trending as its community touts its passive income potential through $SOL rewards, highlighting the project's longevity and upcoming developments. Community members emphasize the ease of earning $SOL simply by holding $IMG, with some suggesting it could revolutionize DeFi. The project is also generating buzz for its participation in the Cypherpunk Hackathon and upcoming live audit technology.

Jelly-My-Jelly

JELLYJELLY is trending due to recent volatility and community excitement around potential breakouts. Traders are actively discussing technical setups and past rallies, while some caution against potential rug pulls after a delisting. The coin is associated with the Solana network and compared to other meme coins, with community members suggesting it may offer substantial gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Retail traders focused on AI-driven biopsy findings and clearer dose-response&nbsp;exuded increased confidence in pemvidutide’s potential.</li><li>Analysts remained divided, with&nbsp;some citing strong MASH resolution and safety, while skeptics questioned differentiation and funding needs.</li><li>Lancet publication and AASLD late-breaker added momentum as Altimmune advanced additional liver-disease programs toward 2026 readouts.</li></ul>Retail discussion around Altimmune intensified over the weekend as investors looked ahead to the 48-week readout from the company’s IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), expected in the fourth quarter of 2025.&nbsp;<h2 class="st-heading-2">AI-Based Biopsy Analysis Adds Fresh Momentum</h2>Last week, Altimmune released results from an AI-based analysis of liver biopsies from the IMPACT Phase 2b trial. The company reported that 31% of patients in the 1.8 mg pemvidutide arm and 12% in the 1.2 mg arm achieved a 60% reduction in total fibrosis, compared with 8% for placebo. Improvements were also observed in early and advanced fibrosis categories, with reductions in the area of fibrosis exceeding 60% in select patient groups compared with placebo.Following the analysis, Citizens JMP lowered its price target to $14 and maintained an ‘Outperform’ rating,&nbsp;noting that&nbsp;it looked ahead to the late-breaking oral presentation at the Liver Meeting and the 48-week dataset expected this quarter. UBS maintained a ‘Buy’ rating, while Jefferies reiterated its ‘Buy’ recommendation, viewing pemvidutide as viable after meeting key histology endpoints at 24 weeks.<h2 class="st-heading-2">Mixed MASH Readout In July Still Shapes Sentiment</h2>Altimmune’s June and July update on its 24-week IMPACT&nbsp;Phase 2b results set the tone for the stock this year.&nbsp;The company reported that up to 59.1% of patients on pemvidutide achieved MASH resolution without worsening of fibrosis, compared to 19.1% for the placebo group. However, the endpoint of fibrosis improvement without worsening of MASH did not reach statistical significance.Despite this, the trial showed reductions in liver fat, inflammation and biomarkers of fibrosis, alongside meaningful weight loss, with up to 6.2% loss in treated patients compared with 1.0% for placebo. Safety remained favorable, with extremely low discontinuations and no drug-related serious adverse events.<h2 class="st-heading-2">Analyst Community Diverges Across The Year</h2>Bullish analysts’ optimism hinged on the drug’s early MASH resolution signal, weight loss trajectory and tolerability. UBS, Stifel, Jefferies and H.C. Wainwright all maintained ‘Buy’ ratings at various points, describing the 24-week results as either differentiated, fast-acting, viable for Phase 3 advancement or supportive of a potential best-in-class profile. Several of these firms highlighted AI-assisted fibrosis reads and non-invasive tests as consistent with anti-fibrotic activity.Others expressed more skepticism. In October, Citizens JMP cut its target earlier, while still keeping an ‘Outperform’ rating. Goldman Sachs resumed coverage with a ‘Sell’ rating, citing a lack of meaningful differentiation in obesity and MASH. Concerns about the company’s ability to fund a full Phase 3 program, especially after the mixed fibrosis outcome, were noted among analysts.<h2 class="st-heading-2">Peer-Reviewed Boost</h2>Last week, Altimmune said that The Lancet had published the 24-week efficacy and safety data from the IMPACT Phase 2b trial. The data were also selected for a late-breaking oral presentation at The Liver Meeting 2025 hosted by AASLD. Investigators highlighted significant MASH resolution, reductions in liver fat, anti-fibrotic signals and weight loss, reinforcing the drug’s potential to treat patients with moderate to advanced fibrosis.<h2 class="st-heading-2">Stocktwits Users See No ‘Breaks’ Ahead</h2>On Stocktwits, retail sentiment for Altimmune was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:972/139;" src="https://news.stocktwits-cdn.com/alt_ss_jpg_da81507313.webp" alt="alt ss.jpg" width="972" height="139"><figcaption>ALT sentiment and message volume as of November 16 | Source: Stocktwits</figcaption></figure>One user discussing the upcoming 48-week dataset pointed to the latest AASLD-published fibrosis odds-ratio findings and the clearer dose-response signals seen in the PathAI-derived analysis, suggesting these results strengthen the case for exploring a higher 2.4 mg dose aimed at accelerating fibrosis reduction, while keeping 1.8 mg and 1.2 mg positioned for broader cardiometabolic use and long-term maintenance.<stembedurl>https://stocktwits.com/BTECHINV/message/636410473</stembedurl>Another user said, “If 48 week MASH data is ‘BEST IN CLASS’ like the weight loss/muscle sparring data, we should get at least $15B for both…not to mention the other indications.”<stembedurl>https://stocktwits.com/Lazarus2024/message/636408646</stembedurl>A third user said, “48 week should confirm fibrosis improvement and we should race to 2 billion MC on it FAST. no breaks once it’s out.”<stembedurl>https://stocktwits.com/SuperPuncher/message/636408207</stembedurl><a href="https://stocktwits.com/symbol/ALT">Altimmune’s stock</a> has declined 42% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment

Retail traders focused on AI-driven biopsy findings and clearer dose-response exuded increased confidence in pemvidutide’s potential.

Equity

FY2025 EPS Estimates for Altimmune Boosted by HC Wainwright

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Analysts at HC Wainwright boosted their FY2025 earnings per share estimates for shares of Altimmune in a research note issued to investors on Tuesday...

Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Altimmune (NASDAQ:ALT - Get Free Report) announced its earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29...

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT Altimmune, Inc. Securities Fraud Class Action Lawsuit...

Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect

ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.

Altimmune, Inc. (ALT) on Thursday said that its mid-stage study of Pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) yielded mixed results, sending shares down 57% in morning trade.Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease characterized by fat accumulation in the liver accompanied by inflammation and cell damage.The trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes. F2 and F3 fibrosis refer to stages of liver fibrosis, with F2 indicating moderate scarring and F3 indicating severe scarring.Up to 59.1% patients enrolled in the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-positive-topline-results-impact-phase-2b">study</a> achieved MASH resolution without worsening of fibrosis at 24 weeks, as compared to merely 19.1% for placebo.However, the percentage of participants in the trial who achieved fibrosis improvement without worsening of MASH in an intent-to-treat analysis as compared to placebo was not statistically significant.Furthermore, only a total of 25.8% and 24.1% of participants receiving pemvidutide 1.2 mg and 1.8 mg, respectively, achieved the endpoint of both MASH resolution and fibrosis improvement, versus 13.5% in participants receiving placebo.Treatment with the drug, however, resulted in weight loss, with a mean weight loss of up to 6.2% in Pemvidutide-treated participants, compared to 1.0% in the placebo arm.Pemvidutide also demonstrated favorable safety and tolerability, with 0.0% and 1.2% adverse events (AE) related discontinuations in the pemvidutide 1.2 mg and 1.8 mg groups versus 2.4% in the placebo group, and there were no serious adverse events (SAEs) related to study medication, the company said.Scott Harris, Chief Medical Officer of Altimmune, expressed optimism about the company holding an end-of-mid-stage trial meeting with the FDA in the fourth quarter of 2025 and rapid progression to late-stage trials following the data.Pemvidutide is an investigational drug in development for the treatment of MASH, obesity, Alcohol Use Disorder (AUD), and Alcohol-associated Liver Disease (ALD).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALT">Altimmune</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_26_at_8_59_53_AM_png_cf1065258b.webp" alt="ALT's Sentiment Meter and Message Volume as of 9:00 a.m. ET on June 26, 2025 | Source: Stocktwits" width="626" height="66"><figcaption>ALT's Sentiment Meter and Message Volume as of 9:00 a.m. ET on June 26, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user, however, opined that the fibrosis improvement data, which was the only thing “worth looking forward to”, was poor, and they see no ground to start a position.<stembedurl>https://stocktwits.com/Ag035/message/619068912</stembedurl>ALT stock is down by 54% this year and by 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-recalls-over-62000-silverado-trucks-in-us-over-fire-concerns/chmOVMWRR4j">General Motors Recalls Over 62,000 Silverado Trucks In US Over Fire Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Altimmune Stock Plummets After Mixed Results In Liver Disease Trial: Retail Sees ‘Nothing Of Substance’ To Start A Position

Altimmune, Inc. (ALT) on Thursday said that its mid-stage study of Pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) yielded mixed results, sending shares down 57% in morning trade.

Up to 59.1% patients enrolled in the study achieved metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis at 24 weeks, as compared to merely 19.1% for placebo.

Altimmune shares jumped during after-hours trading on Wednesday after the biotech firm said it would disclose top-line results from its 24-week Phase 2b IMPACT trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) on Thursday.The stock climbed 7.2% on Tuesday to close at $7.71&nbsp;and extended its rally after hours with a 5.7% gain to $8.15.The upcoming readout is seen as a key milestone for the company’s lead asset, pemvidutide, a GLP-1/glucagon dual receptor agonist being evaluated across multiple liver and metabolic indications, including obesity, alcohol use disorder (AUD), and alcohol-related liver disease (ALD).<a href="https://stocktwits.com/symbol/ALT">Altimmune</a> launched the RECLAIM Phase 2 trial of pemvidutide in AUD in May, aiming to reduce alcohol consumption in a population underserved by current treatment options.&nbsp;The company also plans to begin a Phase 2 study in ALD later this year.Altimmune’s Chief Medical Officer, Scott Harris, previously noted that pemvidutide showed promising reductions in alcohol preference in preclinical models, suggesting potential crossover benefits for metabolic and addictive disorders.Investors will be watching closely on Thursday for signs of efficacy in liver fat reduction, inflammation, and fibrosis, which are endpoints that could position pemvidutide as a competitive candidate in the growing MASH treatment landscape.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said if the data were negative, the company might have quietly published the topline results and followed up later with a management call to explain next steps.&nbsp;<stembedurl>https://stocktwits.com/Micabella/message/619038659</stembedurl>They suggested the only potential delay could be around fibrosis data, which may require the full 48-week readout.Another trader pointed out that if the data were negative, the company might have pushed the announcement into next week’s July 4th holiday lull, when market activity is typically lower.&nbsp;<stembedurl>https://stocktwits.com/Calvary316/message/619038510</stembedurl>Releasing it this Thursday instead, they argued, gives the stock another day to run, a move they believe hints at strong results.The stock has risen 8.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Altimmune Stock Runs Hot Ahead Of MASH Trial Readout; Retail Bulls Eye Big Win

Altimmune launched the RECLAIM Phase 2 trial of pemvidutide in AUD in May, aiming to reduce alcohol consumption in a population underserved by current treatment options. 

Traders are closely watching Thursday’s topline data for signs that pemvidutide could emerge as a competitive treatment in the growing MASH landscape. 

Shares of Altimmune, Inc. (ALT) were in the spotlight on Tuesday morning after the company reported a narrower first-quarter (Q1) loss that was better than Wall Street expectations and secured up to $100 million in credit.Diluted net loss for the three months ended March 31, 2025, was $0.26 per share, compared to a net loss of $0.34 per share in the same period in 2024, and lower than an estimated loss of $0.34 per share, as per Finchat data.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-first-quarter-2025-financial-results-and">company</a> ended the March quarter with cash, cash equivalents, and short-term investments totaling $150 million.Altimmune also entered into a $100 million credit facility with Hercules Capital on Tuesday, with an initial $15 million tranche funded at closing.The company said that an additional $25 million is available in 2025 at Altimmune’s option, subject to the achievement of certain clinical and financial milestones.Altimmune said the remaining $60 million will be available beginning in 2026, with $15 million subject to the achievement of certain clinical and financial milestones and up to $45 million available subject to Hercules's approval. &nbsp;The company said the credit facility significantly increases Altimmune’s financial strength and flexibility.CEO Vipin K. Garg said the company is approaching a number of important milestones. In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).Altimmune also intends to commence phase 2 trials to study pemvidutide in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) in the second and third quarter of this year, respectively.On Stocktwits, retail sentiment around Altimmune jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_10_39_15_AM_png_8bfe41ef98.webp" alt="ALT's Sentiment Meter and Message Volume as of 10:39 a.m. ET on May 13, 2025 | Source: Stocktwits" width="625" height="65"><figcaption>ALT's Sentiment Meter and Message Volume as of 10:39 a.m. ET on May 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ALT">ALT stock</a> is down by 21% this year and by over 23% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/iteos-gsk-end-collaboration-on-experimental-cancer-therapy/chi8V5tRbZi">iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of a biopharmaceutical company | Photo by Bernd Weißbrod/picture alliance via Getty Images

Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased

In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).

Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings? 

Shares of Altimmune Inc. are down more than 23% this year, but that has not deterred retail investors from losing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-after-q4-2024-earnings/chdgfF2RyA">hope</a> in the clinical-stage biotech company.The company has gained traction for its lead candidate,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-on-phase-2-obesity-drug-trial-data/c7zs1ZqRP8">pemvidutide</a>, a GLP-1/glucagon dual receptor agonist being developed for obesity and MASH. In a mid-stage trial, the drug showed that it helped patients reduce their weight by more than 15%.&nbsp;At its R&amp;D Day last week, Altimmune provided more cheer as it unveiled plans to test pemvidutide for treating alcohol use disorder and alcohol-associated liver disease in the second and third quarters of this year.According to The Fly, Evercore ISI said it likes Altimmune's latest expansion and suggested that pemvidutide could rake in more revenue for the new goals than MASH, as 35 million people in the U.S. alone suffer from alcohol use disorder and alcohol-associated liver disease.The research firm added that there is some preclinical and anecdotal evidence to support its thesis.Assuming all goes well, Altimmune will need to fund a Phase 3 program later this year in addition to the AUD/ALD studies, said Evercore, which has an Outperform rating on the shares and a price target of $25.Retail investors on Stocktwits — where Altimmune has over 36,000 followers — have long speculated that the company could be a takeover target. Last year's key&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/alt-stock-slides-after-new-cfo-retail-raises-speculation/cJ4g6IuRO9">C-suite hire</a> at a "pivotal time" for Altimmune bolstered their belief.A Betaville&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.msn.com/en-us/money/companies/altimmune-soars-amid-takeover-speculation/ar-AA1AWioc">report</a> suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms — one FTSE-100 listed, one German, and one U.S.-based — may be involved.<figure class="image"><img style="aspect-ratio:1320/710;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ALT_Stocktwits_poll_on_March_18_png_3a31e58347.webp" alt="ALT Stocktwits poll on March 18.png" width="1320" height="710"><figcaption>ALT Stocktwits poll on March 18. | source: Stocktwits</figcaption></figure>One bullish user said it's "not if, but when [a deal happens]. Too much TAM [total addressable market] for this pipeline of a molecule."<stembedurl>https://stocktwits.com/artiebet/message/608157454</stembedurl>Another user speculated a buyout could happen "within three months," noting the stock is "heading north each week" with "higher lows, higher highs."<stembedurl>https://stocktwits.com/LiveNow1225/message/608159514</stembedurl>Altimmune's stock, which was&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-after-addition-to-nasdaq-biotech-index/cJaozG7RSI">added</a> to the Nasdaq Biotechnology Index (NBI) in December, has a short interest of 28.2%, according to Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail investors on Stocktwits — where Altimmune has over 36,000 followers — have long speculated that the company could be a takeover target. | Image source: Getty Images

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.

Altimmune Shares Sink In 2025, But Retail Traders Are Optimistic About A Buyout

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.


Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with Alphabet ($GOOGL) stock as it hits fresh all-time highs?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.26	--	--	N/A
Q3 '25	-$0.27	-$0.21	22.83%	BEAT
Q2 '25	-$0.34	-$0.27	19.70%	BEAT
Q1 '25	-$0.35	-$0.26	26.12%	BEAT
Q4 '24	-$0.33	-$0.33	0.75%	BEAT

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest ALT News

ALTAltimmune Inc